Continuing Education Activity

Angelman syndrome is a rare neurodevelopmental disorder caused by loss of maternal UBE3A expression on chromosome 15q11.2–q13, resulting in severe developmental delay, absent or minimal speech, epilepsy, ataxia, sleep disturbance, and distinctive behavioral features including frequent laughter and a happy demeanor. Although typically diagnosed in early childhood, variability in genotype and phenotype contributes to delayed recognition and inconsistent management. Management requires coordinated multidisciplinary care focusing on symptom control, particularly seizure management, sleep disturbances, gastrointestinal issues, and orthopedic complications. Although no disease-modifying therapies are currently approved, several investigational approaches, including gene-based therapies targeting UBE3A expression, are advancing in clinical trials. 

This activity reviews the current pathophysiology, diagnostic evaluation using methylation-first testing algorithms, and comprehensive management of Angelman syndrome. This activity also examines the expanding landscape of disease-modifying therapies, including antisense oligonucleotide approaches that are advancing through clinical trials. This activity provides essential knowledge and practical tools to help healthcare professionals recognize Angelman syndrome, improve diagnostic accuracy, and implement evidence-based management strategies. Additional topics include sleep and behavioral interventions, as well as genotype-specific recurrence-risk counseling. The activity emphasizes interprofessional collaboration among healthcare providers to optimize the selection of first-line antiseizure medications, avoid contraindicated agents, improve risk stratification, and prevent common complications, while developing practical clinical skills that support earlier intervention and improve long-term patient-centered outcomes and quality of life.

Objectives:

• Identify the characteristic clinical features and age-dependent presentation of Angelman syndrome to support early recognition and timely referral for molecular testing.
• Apply a stepwise molecular diagnostic algorithm, including first-line methylation analysis and targeted genetic testing, to confirm the diagnosis and determine the underlying mechanism.
• Select evidence-based antiseizure medications and avoid contraindicated agents to reduce seizure exacerbation and medication-related complications.
• Communicate patient-specific seizure risks, contraindicated medications, and monitoring priorities clearly among interprofessional team members to promote safe, coordinated care.

Introduction

Angelman syndrome is a classic genomic imprinting disorder caused by loss of function of the maternally inherited ubiquitin protein ligase E3A gene (UBE3A) on chromosome 15q11.2-q13. British pediatrician Harry Angelman first described this condition in 1965 when he reported 3 children sharing a distinctive constellation of features, including severe developmental delay, absence of speech, ataxic movements, and a uniquely happy disposition with frequent, easily provoked laughter.[1] This phenotype led to the now-deprecated term “happy puppet syndrome” before receiving the eponymous name honoring its discoverer.

The molecular basis of Angelman syndrome lies in genomic imprinting—a process in which gene expression depends on the parental origin. In neurons, the paternal UBE3A allele undergoes transcriptional silencing mediated by the UBE3A antisense transcript (UBE3A-ATS), which is a long noncoding RNA transcribed from the Prader-Willi syndrome imprinting center. This neuron-specific silencing renders individuals entirely dependent on the maternal allele for neuronal UBE3A expression. When the maternal allele is dysfunctional, the resulting absence of UBE3A protein in neurons produces the characteristic features of the syndrome.[2][3] 

UBE3A encodes an E3 ubiquitin ligase critical for synaptic function, dendritic spine morphology, and neuronal plasticity. Loss of this protein disrupts the ubiquitin-proteasome system's ability to regulate key synaptic proteins. Understanding this pathophysiology has opened multiple therapeutic avenues that are now advancing through clinical trials.[4][5]

Etiology

Angelman syndrome is caused by 4 distinct molecular mechanisms, each involving loss of maternal UBE3A function but carrying different implications for phenotypic severity and recurrence risk.[2][3] 

Chromosome 15q11.2-q13 Deletions (70%-75% of Cases)

The most common mechanism involves de novo microdeletions spanning approximately 5 to 7 megabases (Mb). These deletions remove not only UBE3A but also contiguous genes, including GABRB3 (a GABA receptor subunit implicated in seizure susceptibility) and OCA2 (involved in melanin biosynthesis, accounting for hypopigmentation in individuals with deletions). These deletions occur in 2 principal classes: Class I deletions (BP1-BP3, approximately 5.9 Mb) and Class II deletions (BP2-BP3, approximately 5.0 Mb). Recurrence risk is less than 1% unless a maternal chromosomal rearrangement is present.[2]

Paternal Uniparental Disomy (3%-7% of Cases)

Both chromosome 15 homologs are inherited from the father, leaving no maternally derived UBE3A allele. Uniparental disomy (UPD) typically arises from trisomy rescue or monosomy correction. Recurrence risk remains below 1%.[2]

Imprinting Center Defects (3%-5% of Cases)

Pathogenic variants or microdeletions affecting the imprinting center prevent proper establishment of the maternal methylation pattern. Imprinting defects may be inherited, conferring a recurrence risk of up to 50% in carrier mothers.[2]

UBE3A Pathogenic Variants (5%-10% of Cases)

Single-nucleotide variants, small deletions, or insertions directly disrupt the UBE3A gene. These variants may be de novo or maternally inherited; carrier mothers face 50% recurrence risk.[2][6]

Approximately 3% to 10% of individuals meeting clinical criteria have no identifiable molecular abnormality despite comprehensive testing.[2]

Epidemiology

Angelman syndrome affects approximately 1 in 12,000 to 1 in 20,000 live births, with some estimates suggesting a prevalence as high as 1 in 10,000. The condition occurs with equal frequency across sexes and all ethnic groups.[2][7] 

Diagnosis is typically established at a mean age of about 2 years; however, age at diagnosis varies by genotype, with deletion cases identified earlier (mean 1.7 years) than nondeletion cases (mean 2.9 years), reflecting the more distinctive phenotype associated with large deletions.[7]

Data from the Angelman Syndrome Natural History Study, which enrolled more than 450 individuals across North American sites, indicate the following distribution: 71% deletions, 7% paternal UPD, 11% UBE3A pathogenic variants, 3% imprinting defects, and the remainder with unknown mechanisms.[7][8]

Pathophysiology

Angelman syndrome results from the selective loss of functional UBE3A expression in the central nervous system, where the paternal allele is normally silenced and the maternal allele provides the sole source of UBE3A protein. UBE3A functions as an E3 ubiquitin ligase essential for proteasome–mediated protein degradation; loss of UBE3A results in altered synaptic transmission, impaired synaptic plasticity, and disrupted neural circuitry.[2]

The unique GABAergic dysfunction underlies multiple clinical manifestations, including seizure susceptibility, sleep disturbance, and behavioral features. Recent research has demonstrated that individuals with Angelman syndrome have significantly lower respiratory rates during sleep than age-matched controls, suggesting a fundamental dysfunction of respiratory control that reflects underlying GABAergic system abnormalities.[9]

Importantly, antisense oligonucleotide–mediated paternal UBE3A reactivation rescues sleep and electroencephalographic abnormalities even when administered in juvenile or adult mice, suggesting that UBE3A dysfunction remains amenable to therapeutic intervention throughout life.[5]

History and Physical

The clinical presentation follows a characteristic age-dependent evolution, as mentioned below.[2][10]

Infancy (0-12 months): Feeding difficulties are the earliest indicator, often due to poor sucking-swallowing coordination, tongue thrusting, and truncal hypotonia. Findings at birth are often unremarkable.

Late infancy to toddlerhood (6-36 months): Developmental delay typically becomes apparent by 6 to 12 months. Seizures generally appear between 1 and 3 years of age, affecting 80% of individuals by age 3. Relative microcephaly develops by age 2, particularly in patients with deletions. A characteristic happy demeanor, often marked by frequent and unprovoked laughter, also becomes evident over time.

Motor features: The gait, when achieved between ages 2.5 and 6, is characteristically ataxic and wide-based, with arms elevated and flexed. Approximately 10% of individuals never achieve independent walking. Three-dimensional gait analysis shows progressive worsening of a flexed-knee posture during childhood.[11]

Behavioral features: Easily provoked laughter and a happy demeanor are virtually universal. Additional characteristics include hand flapping; mouthing behaviors (95%); short attention span (87%); fascination with water or reflective surfaces (~75%), which may increase the risk of drowning; and hyperactivity, which typically diminishes with age.[2][10]

Speech and communication: Severe expressive speech impairment is universal, with up to 85% of individuals remaining essentially nonverbal. Receptive language exceeds expressive language.[2]

Seizures: Seizure onset typically occurs between ages 12 and 18 months. Reported seizure types include atonic, atypical absence, myoclonic, and generalized tonic-clonic seizures. Seizure burden often improves during puberty but may recur in adulthood.[2]

Sleep disturbances: Sleep disturbances affect 70% to 80% of individuals and are characterized by difficulty initiating and maintaining sleep, decreased sleep requirement, and abnormal circadian rhythm. Most individuals demonstrate markedly reduced nighttime melatonin levels.[2][9]

Physical features in deletion patients: Individuals with deletions commonly exhibit hypopigmentation, defined as lighter skin, hair, and eyes relative to family members, as well as a protruding tongue, wide mouth with widely spaced teeth, prognathism, frequent drooling, and strabismus.[2]

Evaluation

Molecular Diagnostic Algorithm for Angelman Syndrome

Diagnostic evaluation follows a stepwise molecular testing algorithm, with methylation analysis serving as the first-line investigation.[2][12]

• Step 1—Methylation analysis: Methylation-specific multiplex ligation–dependent probe amplification (MLPA) is performed as the initial test and detects approximately 80% of cases. An abnormal result confirms the diagnosis but does not specify the mechanism.
• Step 2—Deletion testing: If methylation analysis is abnormal, deletion testing is performed using chromosomal microarray, fluorescence in situ hybridization (FISH), or MLPA. Approximately 70% of all cases are deletion-positive.
• Step 3—Paternal uniparental disomy: If methylation analysis is abnormal but no deletion is identified, paternal UPD testing is performed using microsatellite analysis with parental samples. If negative, proceed to the imprinting center analysis.
• Step 4—UBE3A gene sequencing: If methylation is normal but clinical suspicion remains high, UBE3A gene sequencing with deletion or duplication analysis is performed. Pathogenic variants in UBE3A are associated with normal methylation patterns.

Electroencephalography

Characteristic abnormalities are observed in 80% to 96% of affected individuals. The most specific finding is notched delta activity, consisting of high-amplitude (200-250 µV) delta waves (2-4 Hz) with superimposed spikes, predominantly in the frontal regions. These findings may appear as early as 4 to 9 months. Delta rhythmicity has been validated as a biomarker correlating with UBE3A expression levels.[2][13]

Additional Assessments

Polysomnography can be used to characterize sleep architecture and detect respiratory dysfunction. The Bayley Scales of Infant and Toddler Development, Fourth Edition (Bayley-4), and the Vineland Adaptive Behavior Scales, Third Edition (Vineland-3), provide standardized assessments of developmental and adaptive functioning. Angelman syndrome–specific outcome measures, including the Symptoms of Angelman Syndrome–Clinician Global Impression (SAS-CGI) and Caregiver-reported Angelman Syndrome Scale (CASS), have been validated for use in clinical trials.[7][14]

Treatment / Management

Management requires a comprehensive, multidisciplinary approach. No disease-modifying therapies are currently approved; however, multiple investigational therapies have progressed to late-stage clinical development.[2][4]

Seizure Management

Seizures affect 80% to 90% of individuals with Angelman syndrome. Epilepsy management involves specific medication considerations that differ substantially from standard epilepsy treatment.[2][15]

Contraindicated medications: The agents below are contraindicated because of documented seizure worsening.[15][16][17]

• Carbamazepine and oxcarbazepine are sodium channel blockers that aggravate absence and myoclonic seizures.
• Vigabatrin paradoxically induces or increases seizure frequency.
• Phenytoin worsens absence and myoclonic seizures.
• Tiagabine is considered potentially harmful according to consensus guidelines.

Preferred first-line medications: The agents below are recommended as first-line therapy for seizure control.[2][15][18]

• Levetiracetam achieves greater than 90% seizure reduction in 86% of individuals.
• Clobazam achieves greater than 90% seizure reduction in 93% of individuals.
• Lamotrigine is particularly effective for atypical absence seizures.
• Topiramate is effective and provides additional weight management benefits.
• Ethosuximide is primarily indicated for absence seizures.

Valproate: Valproate is effective but is associated with motor adverse effects in more than 70% of patients. The 2022 consensus recommends its sparing use, except as a bridge medication or after failure of other anticonvulsants.[2]

Dietary therapy: The low glycemic index treatment is associated with complete seizure freedom in 22% of individuals and seizure freedom, except during intercurrent illness, in an additional 43%.[19]

Status epilepticus: Nonconvulsive status epilepticus occurs in 35% to 85% of patients. Rescue medications should be readily available for all patients.[2]

Sleep Management

Sleep disturbances are common and contribute significantly to caregiver burden.

• Behavioral interventions are first-line and include consistent sleep hygiene practices, low-light evening environments, and enclosed sleeping arrangements.[2]
• Melatonin has demonstrated efficacy in randomized controlled trials. Doses of 0.3 to 5 mg reduce sleep latency by 32 minutes and increase total sleep time by 56 minutes.[20]

Gastrointestinal Management

Gastrointestinal manifestations affect 86.5% of individuals. Constipation affects 80% to 85% of individuals and may contribute to increased seizure frequency. Gastroesophageal reflux disease affects 45% to 65% of individuals. The risk of aspiration necessitates evaluation by speech-language pathology services.[21]

Orthopedic Management

Scoliosis affects 20% of children and 50% of adults, and 24% of affected individuals require surgical intervention. Physical therapy improves mobility and helps prevent secondary complications.[2]

Communication Intervention

Speech and language therapy, with an emphasis on augmentative and alternative communication, should be initiated at diagnosis. Systematic review evidence confirms the viability of alternative communication for enhancing communication.[22]

Emerging Therapies (All Investigational)

Multiple disease-modifying therapies are currently advancing through clinical trials.[4][5][23]

Antisense Oligonucleotide Therapies

Antisense oligonucleotide therapies target UBE3A-ATS, a long noncoding RNA that silences the paternal UBE3A allele, leading to transcript degradation and restoration of UBE3A protein expression.

• GTX-102 (Ultragenyx): The Phase 3 ASPIRE trial fully enrolled 129 participants in July 2025, and results are expected in the second half of 2026. The therapy received FDA Breakthrough Therapy Designation in June 2025.[4]
• ION582 (Ionis): The Phase 3 REVEAL study was initiated in early 2025. The therapy received FDA Breakthrough Therapy Designation in September 2025 and has not demonstrated lower extremity weakness (Ionis Pharmaceuticals; ION582 FDA Breakthrough Therapy Designation for Angelman Syndrome).
• Rugonersen (Oak Hill Bio): Phase 1 results demonstrated dose-dependent normalization of electroencephalography patterns in 61 children.[23]

Gene Therapy

MVX-220 (MavriX Bio): AAV9–mediated UBE3A delivery entered Phase 1/2 trials, with the first patient dosed in 2025 (MavriX Bio; MVX-220 ASCEND-AS Trial Enrollment Initiated (https://www.mavrixbio.com/news/mvx220-first-patient).

Differential Diagnosis

Several neurodevelopmental disorders share similar clinical features with Angelman syndrome. The principal conditions are outlined below.[2]

• Rett syndrome (MECP2): This condition is characterized by regression after a period of normal development, hand stereotypies, and predominance in females.
• Pitt-Hopkins syndrome (TCF4): This condition is characterized by breathing abnormalities, including hyperventilation and apnea, as well as distinctive facies.
• Christianson syndrome (SLC9A6): This X-linked disorder is associated with cerebellar and brainstem atrophy on magnetic resonance imaging (MRI).
• Mowat-Wilson syndrome (ZEB2): This condition is characterized by Hirschsprung disease and distinctive facies.
• Kleefstra syndrome (EHMT1): This condition is characterized by distinctive facial features and a characteristic behavioral profile.
• Prader-Willi syndrome: This condition is characterized by loss of paternally expressed genes due to abnormal imprinting and presents with hypotonia, hyperphagia, obesity, and infrequent seizures.

Prognosis

Angelman syndrome is not degenerative. Overall health remains generally good, and affected individuals have a near-normal to normal life expectancy, with the oldest documented individual reaching 83 years of age.[8][10]

Outcomes vary substantially by genotype. Individuals with deletions demonstrate the most severe phenotype, characterized by earlier and more refractory seizures, absent speech, and greater motor impairment. By age 15, individuals with deletions have a 50% probability of acquiring 17 of 30 measured adaptive skills, compared with 25 of 30 skills among individuals without deletions.[8][10]

Leading causes of death vary by age, with seizures and accidents predominating in young children and pneumonia in older adults. Sudden unexpected death in sleep has also been reported as a cause of mortality.[24] Most adults require lifelong care and 24-hour supervision.[25] Seizures often improve during puberty but may recur in the third or fourth decades of life. Sleep generally improves with age, and hyperactivity diminishes. The characteristic happy demeanor typically persists throughout life.[2][10]

Complications

Epilepsy-related complications include treatment-resistant seizures (84% of individuals experience refractory epilepsy during early childhood), status epilepticus, and seizure-related injuries. Medication-related complications include motor deterioration associated with valproate and paradoxical seizure worsening associated with contraindicated agents.[2]

Orthopedic complications include progressive scoliosis requiring surgical intervention in approximately one-quarter of affected individuals, joint contractures, and decreased bone density.[2]

Aspiration pneumonia occurs secondary to gastroesophageal reflux disease, feeding difficulties, and excessive drooling and represents a major cause of hospitalization and mortality.[2][21]

Behavioral complications include self-injurious behavior (52% of adults), aggressive behavior, and anxiety that tends to worsen with age.[10]

Deterrence and Patient Education

Families should receive comprehensive education regarding seizure recognition and emergency management, including the identification of subtle presentations of nonconvulsive status epilepticus. All families should have rescue medications readily available. Education regarding contraindicated medications is critical, as inappropriate prescribing of carbamazepine or vigabatrin by providers unfamiliar with Angelman syndrome may result in serious harm.[2]

Genetic counseling addresses recurrence risk, which varies by mechanism from less than 1% for typical deletions to 50% for inherited UBE3A pathogenic variants or imprinting-centered deletions. Extended family testing is indicated when inherited forms are identified.[2]

Transition planning should begin at ages 15 to 16 and address guardianship, vocational training, residential options, and eligibility for developmental disability services. Family support resources include the Angelman Syndrome Foundation and the Foundation for Angelman Syndrome Therapeutics.[2]

Enhancing Healthcare Team Outcomes

Angelman syndrome is a complex neurodevelopmental disorder that requires coordinated, interprofessional collaboration across multiple specialties. In the absence of curative therapy, management aims to control symptoms and improve quality of life through early diagnosis, comprehensive intervention, and family-centered care.[2]

Once Angelman syndrome is suspected, the patient should be evaluated by an interprofessional healthcare team. Clinicians apply an understanding of the molecular mechanisms, age-dependent clinical presentation, and a stepwise diagnostic algorithm that includes methylation analysis and targeted genetic testing. Neurologists lead epilepsy management by interpreting electroencephalography findings and selecting appropriate antiseizure medications while avoiding contraindicated agents such as carbamazepine, oxcarbazepine, and vigabatrin. They should be aware of the paradigm shift toward levetiracetam and clobazam as first-line therapies. Geneticists and genetic counselors establish molecular diagnoses, provide recurrence-risk counseling, and coordinate family testing when indicated.

Pharmacists serve an essential safety function in medication verification. Given the specific contraindications associated with epilepsy in Angelman syndrome, pharmacist review of all antiseizure medication prescriptions can prevent inadvertent harm. Pharmacists must verify that prescribed antiseizure medications are not contraindicated and communicate directly with prescribers when these agents are ordered.

Nurses provide frontline seizure recognition and emergency management, monitor for aspiration risk during feeding, educate caregivers on seizure recognition and rescue medication administration, and maintain sleep diaries, which are essential for treatment optimization. Physical and occupational therapists address motor deficits, prescribe appropriate orthotic devices, monitor scoliosis progression, and implement gait training programs. Speech-language pathologists conduct swallowing evaluations to assess aspiration risk, implement alternative communication systems, and train families in communication strategies.

Early intervention, developmental evaluation, and therapy should begin during infancy to optimize developmental outcomes. Initial family meetings and regular follow-up visits help caregivers remain actively involved in care. Evidence supports the conclusion that early diagnosis and coordinated interprofessional treatment improve outcomes for individuals with Angelman syndrome.[2][7]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Williams CA, Angelman H, Clayton-Smith J, Driscoll DJ, Hendrickson JE, Knoll JH, Magenis RE, Schinzel A, Wagstaff J, Whidden EM. Angelman syndrome: consensus for diagnostic criteria. Angelman Syndrome Foundation. Am J Med Genet. 1995 Mar 27;56(2):237-8. [PubMed: 7625452]

2.

Duis J, Nespeca M, Summers J, Bird L, Bindels-de Heus KGCB, Valstar MJ, de Wit MY, Navis C, Ten Hooven-Radstaake M, van Iperen-Kolk BM, Ernst S, Dendrinos M, Katz T, Diaz-Medina G, Katyayan A, Nangia S, Thibert R, Glaze D, Keary C, Pelc K, Simon N, Sadhwani A, Heussler H, Wheeler A, Woeber C, DeRamus M, Thomas A, Kertcher E, DeValk L, Kalemeris K, Arps K, Baym C, Harris N, Gorham JP, Bohnsack BL, Chambers RC, Harris S, Chambers HG, Okoniewski K, Jalazo ER, Berent A, Bacino CA, Williams C, Anderson A. A multidisciplinary approach and consensus statement to establish standards of care for Angelman syndrome. Mol Genet Genomic Med. 2022 Mar;10(3):e1843. [PMC free article: PMC8922964] [PubMed: 35150089]

3.

Dagli AI, Mathews J, Williams CA. Angelman Syndrome. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews^® [Internet]. University of Washington, Seattle; Seattle (WA): Sep 15, 1998. [PubMed: 20301323]

4.

Dindot SV, Christian S, Murphy WJ, Berent A, Panagoulias J, Schlafer A, Ballard J, Radeva K, Robinson R, Myers L, Jepp T, Shaheen H, Hillman P, Konganti K, Hillhouse A, Bredemeyer KR, Black L, Douville J., FIRE consortium. FIRE Consortium. An ASO therapy for Angelman syndrome that targets an evolutionarily conserved region at the start of the UBE3A-AS transcript. Sci Transl Med. 2023 Mar 22;15(688):eabf4077. [PubMed: 36947593]

5.

Lee D, Chen W, Kaku HN, Zhuo X, Chao ES, Soriano A, Kuncheria A, Flores S, Kim JH, Rivera A, Rigo F, Jafar-Nejad P, Beaudet AL, Caudill MS, Xue M. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome. Elife. 2023 Jan 03;12 [PMC free article: PMC9904759] [PubMed: 36594817]

6.

Beygo J, Buiting K, Ramsden SC, Ellis R, Clayton-Smith J, Kanber D. Update of the EMQN/ACGS best practice guidelines for molecular analysis of Prader-Willi and Angelman syndromes. Eur J Hum Genet. 2019 Sep;27(9):1326-1340. [PMC free article: PMC6777528] [PubMed: 31235867]

7.

Tjeertes J, Bacino CA, Bichell TJ, Bird LM, Bustamante M, Crean R, Jeste S, Komorowski RW, Krishnan ML, Miller MT, Nobbs D, Ochoa-Lubinoff C, Parkerson KA, Rotenberg A, Sadhwani A, Shen MD, Squassante L, Tan WH, Vincenzi B, Wheeler AC, Hipp JF, Berry-Kravis E. Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS). J Neurodev Disord. 2023 Jul 26;15(1):22. [PMC free article: PMC10373389] [PubMed: 37495977]

8.

Keute M, Miller MT, Krishnan ML, Sadhwani A, Chamberlain S, Thibert RL, Tan WH, Bird LM, Hipp JF. Angelman syndrome genotypes manifest varying degrees of clinical severity and developmental impairment. Mol Psychiatry. 2021 Jul;26(7):3625-3633. [PMC free article: PMC8505254] [PubMed: 32792659]

9.

den Bakker H, Sidorov MS, Fan Z, Lee DJ, Bird LM, Chu CJ, Philpot BD. Abnormal coherence and sleep composition in children with Angelman syndrome: a retrospective EEG study. Mol Autism. 2018;9:32. [PMC free article: PMC5924514] [PubMed: 29719672]

10.

Larson AM, Shinnick JE, Shaaya EA, Thiele EA, Thibert RL. Angelman syndrome in adulthood. Am J Med Genet A. 2015 Feb;167A(2):331-44. [PMC free article: PMC5534346] [PubMed: 25428759]

11.

Beckung E, Steffenburg S, Kyllerman M. Motor impairments, neurological signs, and developmental level in individuals with Angelman syndrome. Dev Med Child Neurol. 2004 Apr;46(4):239-43. [PubMed: 15077701]

12.

Buiting K, Williams C, Horsthemke B. Angelman syndrome - insights into a rare neurogenetic disorder. Nat Rev Neurol. 2016 Oct;12(10):584-93. [PubMed: 27615419]

13.

Sidorov MS, Deck GM, Dolatshahi M, Thibert RL, Bird LM, Chu CJ, Philpot BD. Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis. J Neurodev Disord. 2017;9:17. [PMC free article: PMC5422949] [PubMed: 28503211]

14.

Connor-Ahmad S, Tjeertes J, Chladek M, Newton L, Symonds T, Clinch S, Vincenzi B, McDougall F. Developing Angelman syndrome-specific clinician-reported and caregiver-reported measures to support holistic, patient-centered drug development. Orphanet J Rare Dis. 2023 Jun 22;18(1):156. [PMC free article: PMC10288761] [PubMed: 37349793]

15.

Samanta D. Epilepsy in Angelman syndrome: A scoping review. Brain Dev. 2021 Jan;43(1):32-44. [PMC free article: PMC7688500] [PubMed: 32893075]

16.

Valente KD, Koiffmann CP, Fridman C, Varella M, Kok F, Andrade JQ, Grossmann RM, Marques-Dias MJ. Epilepsy in patients with angelman syndrome caused by deletion of the chromosome 15q11-13. Arch Neurol. 2006 Jan;63(1):122-8. [PubMed: 16401744]

17.

Ostergaard JR, Balslev T. Efficacy of different antiepileptic drugs in children with Angelman syndrome associated with 15q11-13 deletion: the Danish experience. Dev Med Child Neurol. 2001 Oct;43(10):718-9. [PubMed: 11665831]

18.

Thibert RL, Conant KD, Braun EK, Bruno P, Said RR, Nespeca MP, Thiele EA. Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. Epilepsia. 2009 Nov;50(11):2369-76. [PubMed: 19453717]

19.

Grocott OR, Herrington KS, Pfeifer HH, Thiele EA, Thibert RL. Low glycemic index treatment for seizure control in Angelman syndrome: A case series from the Center for Dietary Therapy of Epilepsy at the Massachusetts General Hospital. Epilepsy Behav. 2017 Mar;68:45-50. [PubMed: 28109989]

20.

Braam W, Didden R, Smits MG, Curfs LM. Melatonin for chronic insomnia in Angelman syndrome: a randomized placebo-controlled trial. J Child Neurol. 2008 Jun;23(6):649-54. [PubMed: 18539989]

21.

Glassman LW, Grocott OR, Kunz PA, Larson AM, Zella G, Ganguli K, Thibert RL. Prevalence of gastrointestinal symptoms in Angelman syndrome. Am J Med Genet A. 2017 Oct;173(10):2703-2709. [PubMed: 28816003]

22.

Calculator SN, Black T. Validation of an inventory of best practices in the provision of augmentative and alternative communication services to students with severe disabilities in general education classrooms. Am J Speech Lang Pathol. 2009 Nov;18(4):329-42. [PubMed: 19638486]

23.

Hipp JF, Bacino CA, Bird LM, Bruenig-Traebert I, Chan D, de Wit MC, Fontoura P, Hooper G, Jagasia R, Krishnan ML, Murtagh L, Noci A, Martínez AR, Schwab D, Serrano M, Shen MD, Tillmann J, Tjeertes J, Vincenzi B, Berry-Kravis E, Bonni A., Rugonersen Study Group. all TANGELO investigators. The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trial. Nat Med. 2025 Sep;31(9):2936-2945. [PubMed: 40646322]

24.

Fiumara A, Pittalà A, Cocuzza M, Sorge G. Epilepsy in patients with Angelman syndrome. Ital J Pediatr. 2010 Apr 16;36:31. [PMC free article: PMC2865483] [PubMed: 20398390]

25.

Wheeler AC, Sacco P, Cabo R. Unmet clinical needs and burden in Angelman syndrome: a review of the literature. Orphanet J Rare Dis. 2017 Oct 16;12(1):164. [PMC free article: PMC5644259] [PubMed: 29037196]

Disclosure: Manik Madaan declares no relevant financial relationships with ineligible companies.

Disclosure: Andres Morales declares no relevant financial relationships with ineligible companies.